Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."

Sales Check With Hudson's Bay CEO Jerry Storch
36:22 - Hudson's Bay CEO Jerry Storch weighs in on Black Friday sales. He speaks on "Bloomberg Markets." (Source: Bloomberg)
  • Black Friday Retail Sales: The Winners & the Losers
  • Battle of the Charts: Retail Traffic, Euro Versus Dollar
  • 2016 Will Be a Better Year for Stocks, Here's Why